There is no commercial support for this activity.

About The Speaker

Tammy Miller is a clinical psychologist that works full time in the Sheppard Pratt research department.  She is the lead psychotherapist for the psilocybin research trials being conducted at Sheppard Pratt. She is also a mentor and trainer for other psilocybin therapists.  Tammy has prior experience working in crisis work, outpatient community health,  inpatient hospitals, and private practice.  Tammy knew that she wanted to make meaningful contributions to society and discovered her passion in working in mental health and helping others.   When not working you can find Tammy spending time with her family, listening to music, and traveling.    

Stephanie Peck is a clinical psychologist and Associate Clinical Professor at the UC San Diego School of Medicine. She is co-investigator on two FDA-approved  trials evaluating psilocybin for eating disorders and acted as lead psychologist on a Phase 2b FDA approved trial evaluating psilocybin for treatment resistant depression. She has extensive experience delivering both psilocybin therapy and ketamine-assisted therapy. For the past 3.5 years, Stephanie has delivered psychedelic treatment in academic clinical research settings. She also serves as a therapist trainer and mentor to therapists delivering psilocybin therapy through clinical research trials.  Dr. Peck is a consultant for Compass Pathways, the life sciences company involved in bringing psychedelic treatment to market. She is a subject matter expert and has served as a content developer for the treatment and therapist training program for upcoming clinical trials. In addition to her work in psychedelics, Dr. Peck directs a treatment program for adolescents and adults at the UCSD Eating Disorders Treatment Center and is involved with program development. 

Nadav (Liam) Modlin is the Psychology & Psychotherapy Lead in Psychedelics at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London. With an interest in psychopharmacology and clinical expertise in treating psychological trauma, at the IoPPN Liam works as a research therapist, therapist trainer, and clinical investigator on studies exploring the safety and efficacy of psychedelics. As part of his doctoral studies, Liam conducts trauma-focused qualitative research investigating patients’ perspectives around traumatic stress symptoms, and experience of currently available and experimental treatments. His lectures at the IoPPN explore psychotherapeutic models in clinical trials investigating the safety and efficacy of psychedelics, the potential applications of psychedelic therapy in military populations and psychotherapy in affective disorders. He is also the co-founder of the Maudsley Psychedelic Society Harm Reduction 'Integration' Group. Based in London, Liam has a private counselling & psychotherapy practice and has worked in various NHS mental health services delivering psychodynamic psychotherapy and as a team lead.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers, speakers and persons in control of content have been asked to disclose any relationship he /she has with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

Tammy M. Miller, PsyD, reports that she is a consultant Compass Pathways. She will discuss the off-label use of psilocybin in this presentation. This speaker will be only discussing research findings, discovery, and modalities in this presentation. No specific products or services will be discussed. All conflicts have been mitigated through review. 

Stephanie Knatz Peck, PhD reports that she is a consultant and subject matter expert for Compass Pathways. She will discuss the off-label use of psilocybin in this presentation.  This speaker will be only discussing research findings, discovery, and modalities in this presentation. No specific products or services will be discussed. All conflicts have been mitigated through review. 

Nadav Modlin, MSc, MBACP,  reports that he is a consultant for Compass Pathways, Small Pharma, and Psytech. He will discuss the off-label use of psilocybin in this presentation. This speaker will be only discussing research findings, discovery, and modalities in this presentation. No specific products or services will be discussed. All conflicts have been mitigated through review. 

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, selling, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 24 months: Todd Peters, MD, Deepak Prabhakar, MD, Elizabeth Ryznar, MD, MSc., Louis Marino, MD, Ehsan Syed, MD, Devi Bhuyan, PsyD, Faith Dickerson, PhD, Carrie Etheridge, LCSW-C, Tom Flis, LCPC, Laura Webb, RN-BC, MSN, Stacey Garnett, RN, MSN, Heather Billings, RN, Octavia Coit, MN, Lisa Illum MLIS, MEd, and Jennifer Tornabene.